Grant of patent in Japan

In brief · summary, not quotable

Fusion Antibodies plc has been granted patent number 7853096 by the Japan Patent Office for its "Antibody Library and Method," which covers two families of antibodies and their design methodology, strengthening its antibody discovery platform and potential licensing opportunities. This patent is expected to complement the company's "Opti" designed antibody libraries for applications including discovery, affinity maturation, and sequence optimization. Fusion is also pursuing additional patent applications for its OptiMAL® Library in Europe and China, aiming to expand the global reach of its antibody technologies and support future licensing deals.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your FAB notes

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the Company's patent application no. 2021-519644 has been formally granted by the Japan Patent Office (the "Japanese Patent Office") under Japanese Patent no. 7853096 (the "Patent").

The Patent, entitled "Antibody Library and Method", covers two families of antibodies, and the method for the design of such antibody libraries. The Patent is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation.

The Company is also progressing additional patent applications in respect of the OptiMAL® Library in Japan and several other territories worldwide including Europe and China.

Richard Buick, CSO of Fusion, said: "I am really pleased that the Japanese Patent Office has granted this approval. This confirms our unique approach to antibody library design and protects these families of antibodies. Furthermore with this recognition in Japan, we are continuing to advance our global strategy to expand the reach and impact of our Opti designed antibody technologies."

Adrian Kinkaid, CEO of Fusion, said: "This excellent news lays the foundations for potential future licensing deals and complements our strategy to protect OptiMAL®. This patent marks an important milestone in strengthening our platform and reinforces our commitment to delivering high quality antibody solutions for both therapeutic and diagnostic innovation. With this significant step, we are accelerating our mission to transform how antibodies are designed, discovered, and optimised worldwide."

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.